Form 8-K - Current report:
SEC Accession No. 0001000694-24-000009
Filing Date
2024-02-28
Accepted
2024-02-28 08:07:50
Documents
16
Period of Report
2024-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nvax-20240228.htm   iXBRL 8-K 35720
2 EX-99.1 a4q23earningspressrelease2.htm EX-99.1 81065
6 final-novavaxxlogoxcmyka.jpg GRAPHIC 259586
  Complete submission text file 0001000694-24-000009.txt   589523

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvax-20240228.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nvax-20240228_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvax-20240228_pre.xml EX-101.PRE 12520
17 EXTRACTED XBRL INSTANCE DOCUMENT nvax-20240228_htm.xml XML 2712
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 24690268
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)